Comparison of Different Matrices as Potential Quality Control Samples for Neurochemical Dementia Diagnostics

Lelental, Natalia; Brandner, Sebastian; Kofanova, Olga; Blennow, Kaj; Zetterberg, Henrik; Andréasson, Ulf; Engelborghs, Sebastiaan; Mroczko, Barbara; Gabryelewicz, Tomasz; Teunissen, Charlotte E.; Mollenhauer, Brit; Parnetti, Lucilla; Chiasserini, Davide; Molinuevo, José Luís; Perret‐Liaudet, Armand; Verbeek, Marcel M.; Andreasen, Niels; Brosseron, Frederic; Bahl, Justyna M.C.; Herukka, Sanna Kaisa; Hausner, Lucrezia; Frölich, Lutz; Labonté, Anne; Poirier, Judes; Miller, Anne Marie; Žilka, Norbert; Kováčech, Branislav; Urbani, Andrea; Suardi, Silvia; Oliveira, Catarina R.; Baldeiras, Inês; Dubois, Bruno; Rot, Uroš; Lehmann, Sylvain; Skinningsrud, Anders; Betsou, Fay; Wiltfang, Jens; Gkatzima, Olymbia; Winblad, Bengt; Buchfelder, Michael; Kornhuber, Johannes; Lewczuk, Piotr

doi:10.3233/jad-150883

Cited by 19 publications

(16 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The CSF samples were analyzed by ELISA assays for Aβ 1–42 (IBL International 207 GmbH, Hamburg, Germany, Fujirebio Europe, formely Innogenetics, Ghent, Belgium), phosphorylated tau 181 (p‐ tau ) and total tau ( tau ) (Fujirebio 211 Europe) according to the instruction of the manufacturers and a standardized protocol developed by the BIOMARKAPD consortium (Lelental et al, ).…”

Section: Methodsmentioning

confidence: 99%

Regionally specific changes in the hippocampal circuitry accompany progression of cerebrospinal fluid biomarkers in preclinical Alzheimer's disease

Tardif

Devenyi

Amaral

et al. 2017

Human Brain Mapping

Self Cite

View full text Add to dashboard Cite

Neuropathological and in vivo brain imaging studies agree that the cornu ammonis 1 and subiculum subfields of the hippocampus are most vulnerable to atrophy in the prodromal phases of Alzheimer's disease (AD). However, there has been limited investigation of the structural integrity of the components of the hippocampal circuit, including subfields and extra-hippocampal white matter structure, in relation to the progression of well-accepted cerebrospinal fluid (CSF) biomarkers of AD, amyloid-β 1-42 (Aβ) and total-tau (tau). We investigated these relationships in 88 aging asymptomatic individuals with a parental or multiple-sibling familial history of AD. Apolipoprotein (APOE) ɛ4 risk allele carriers were identified, and all participants underwent cognitive testing, structural magnetic resonance imaging, and lumbar puncture for CSF assays of tau, phosphorylated-tau (p-tau) and Aβ. Individuals with a reduction in CSF Aβ levels (an indicator of amyloid accretion into neuritic plaques) as well as evident tau pathology (believed to be linked to neurodegeneration) exhibited lower subiculum volume, lower fornix microstructural integrity, and a trend towards lower cognitive score than individuals who showed only reduction in CSF Aβ. In contrast, persons with normal levels of tau showed an increase in structural MR markers in relation to declining levels of CSF Aβ. These results suggest that hippocampal subfield volume and extra-hippocampal white matter microstructure demonstrate a complex pattern where an initial volume increase is followed by decline among asymptomatic individuals who, in some instances, may be a decade or more away from onset of cognitive or functional impairment.

show abstract

Section: Methodsmentioning

confidence: 99%

Regionally specific changes in the hippocampal circuitry accompany progression of cerebrospinal fluid biomarkers in preclinical Alzheimer's disease

Tardif

Devenyi

Amaral

et al. 2017

Human Brain Mapping

Self Cite

View full text Add to dashboard Cite

show abstract

“…Measurements on samples left at RT for longer than 24 hours have been more variable, with studies reporting increasing [100,129] or decreasing [130] CSF Aβ(1-42) concentration, or no effect [131][132][133]. Hypotheses for the increase or decrease include Aβ(1-42) release from amyloid-binding proteins [100], increased Aβ adsorption to tube material [83], or proteolytic degradation [129].…”

Section: Temperature Between Collection and Analysis/storagementioning

confidence: 99%

“…Investigations have consistently shown that CSF biomarkers (Aβ(1-42), pTau and tTau) are reasonably stable over time, when stored at -80°C (Table 3; [ 73,123,130,131,133,134,[137][138][139][140]); a recent study found that, if using a single batch of assays following varying sample storage times, storage for up to 12 years had no significant effect [140]. Only one report was found in this review that deviated from this, describing an increase in concentration of some samples following 7 months [138].…”

Section: Storage Durationmentioning

confidence: 99%

The impact of preanalytical variables on measuring cerebrospinal fluid biomarkers for Alzheimer's disease diagnosis: A review

Hansson

Mikulskis

Fagan

et al. 2018

Alzheimer's & Dementia

Self Cite

102

110

View full text Add to dashboard Cite

show abstract

“…For example, Bjerke et al [17] reported that only native CSF without additives is commutable for multiple method comparisons, including mass spectrometry. In addition, the selection of the matrix type for use as a quality control sample in the assay is important [18], while the effect of changes in biomarker concentrations on clinical decision-making must be documented for each analyte [19]. If needed, statistical approaches are available for harmonization of results between study designs or between sample processing procedures [20].…”

Section: Discussionmentioning

confidence: 99%

Recommendations for cerebrospinal fluid collection for the analysis by ELISA of neurogranin trunc P75, α-synuclein, and total tau in combination with Aβ(1–42)/Aβ(1–40)

Vanderstichele¹,

Demeyer²,

Janelidze

et al. 2017

Alz Res Therapy

View full text Add to dashboard Cite

BackgroundThe pathophysiology of neurodegeneration is complex. Its diagnosis requires an early identification of sequential changes in several hallmarks in the brains of affected subjects. The presence of brain pathology can be visualized in the cerebrospinal fluid (CSF) by protein profiling. It is clear that the field of Alzheimer’s disease (AD) will benefit from an integration of algorithms including CSF concentrations of individual proteins, especially as an aid in clinical decision-making or to improve patient enrolment in clinical trials. The protein profiling approach requires standard operating procedures for collection and storage of CSF which must be easy to integrate into a routine clinical lab environment. Our study provides recommendations for analysis of neurogranin trunc P75, α-synuclein, and tau, in combination with the ratio of β-amyloid Aβ(1–42)/Aβ(1–40).MethodsProtocols for CSF collection were compared with CSF derived from subjects with normal pressure hydrocephalus (n = 19). Variables included recipient type (collection, storage), tube volume, and addition of detergents at the time of collection. CSF biomarker analysis was performed with enzyme-linked immunosorbent assays (ELISAs). Data were analyzed with linear repeated measures and mixed effects models.ResultsAdsorption to recipients is lower for neurogranin trunc P75, α-synuclein, and tau (<10%), as compared to Aβ(1–42). For neurogranin trunc P75 and total tau, there is still an effect on analyte concentrations as a function of the tube volume. Protocol-related differences for Aβ(1–42) can be normalized at the (pre-)analytical level using the ratio Aβ(1–42)/Aβ(1–40), but not by using the ratio Aβ(1–42)/tau. The addition of detergent at the time of collection eliminates differences due to adsorption.ConclusionsOur study recommends the use of low protein binding tubes for quantification in CSF (without additives) of all relevant CSF biomarkers. Pre-analytical factors have less effect on α-synuclein, neurogranin trunc P75, and total tau, as compared to Aβ(1–42). The ratio of Aβ(1–42)/Aβ(1–40), but not Aβ(1–42)/tau, can be used to adjust for pre-analytical differences in analyte concentrations. Our study does not recommend the inclusion of detergents at the time of collection of CSF. The present results provide an experimental basis for new recommendations for parallel analysis of several proteins using one protocol for collection and storage of CSF.Electronic supplementary materialThe online version of this article (doi:10.1186/s13195-017-0265-7) contains supplementary material, which is available to authorized users.

show abstract

Comparison of Different Matrices as Potential Quality Control Samples for Neurochemical Dementia Diagnostics

Abstract: Our results suggest that it is possible to replace self-made, CSF-based QC samples with large-scale volumes of QC materials prepared with artificial peptides and matrices. This would greatly facilitate intra- and inter-laboratory QC schedules for NDD measurements.

Cited by 19 publications

References 20 publications

Regionally specific changes in the hippocampal circuitry accompany progression of cerebrospinal fluid biomarkers in preclinical Alzheimer's disease

Regionally specific changes in the hippocampal circuitry accompany progression of cerebrospinal fluid biomarkers in preclinical Alzheimer's disease

The impact of preanalytical variables on measuring cerebrospinal fluid biomarkers for Alzheimer's disease diagnosis: A review

Recommendations for cerebrospinal fluid collection for the analysis by ELISA of neurogranin trunc P75, α-synuclein, and total tau in combination with Aβ(1–42)/Aβ(1–40)

Contact Info

Product

Resources

About